Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DPC enters HBV market

This article was originally published in The Gray Sheet

Executive Summary

Diagnostic Products Corp.'s hepatitis B virus test U.S. market entry Aug. 1 more than doubles the Los Angeles firm's infectious disease market potential, company says. The domestic HBV market is estimated at $300-500 mil. DPC entered the U.S. infectious disease market three years ago with tests for rubella, CMV, herpes and toxoplasmosis - a market opportunity less than half that for HBV, according to the firm. On July 31, DPC announced FDA approval of nine in vitro HBV assays for use on the Immulite and Immulite 2000 automated, chemiluminescent platforms, including two HBsAg, one HBsAg confirmatory, two Anti-HBs, two Anti-HBc and two Anti-HBc IgM tests...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016964

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel